The RNA Binding Protein Bcas2 is Required for Antibody Class Switch in Activated-B Cells

Abstract

In children, hyper-IgM syndrome type 1 (HIGM1) is a type of severe antibody disorder, the pathogenesis of which remains unclear. The antibody diversity is partially determined by the alternative splicing (AS) in the germline, which is mainly regulated by RNA-binding proteins, including Breast cancer amplified sequence 2 (Bcas2). However, the effect of Bcas2 on AS and antibody production in activated B cells, the main immune cell type in the germline, remains unknown. To fill this gap, we created a conditional knockout (cKO, B cell-specific AID-Cre Bcas2^fl/fl) mouse model and performed integrated mechanistic analysis on alternative splicing (AS) and CSR in B cells through the RNA-sequencing approach, cross-linking immunoprecipitation and sequencing (CLIP-seq) analysis, and interactome proteomics. The results demonstrate that Bcas2-cKO significantly decreased CSR in activated B cells without inhibiting the B cell development. Mechanistically, Bcas2 interacts with SRSF7 at a conservative circular domain, forming a complex to regulate the AS of genes involved in the post-switch transcription, thereby causing broad-spectrum changes in antibody production. Importantly, we identified GAAGAA as the binding motif of Bcas2 to RNAs and revealed its essential role in the regulation of Bcas2-dependent AS and CSR. In addition, we detected a mutation of at the 3’UTR of Bcas2 gene in children with HIGM1 and observed similar patterns of AS events and CSR in the patient that were discovered in the Bcas2-cKO B cells. Combined, our study elucidates the mechanism by which Bcas2-mediated AS affects CSR, offering potential insights into the clinical implications of Bcas2 in HIGM1.

Keywords

alternative splicing / Bcas2 / class switch recombination / CLIP-seq / hyper-IgM syndrome type 1 / RNA binding proteins

References

[1] J. A. Roco, L. Mesin, S. C. Binder, et al., “Class-Switch Recombination Occurs Infrequently in Germinal Centers,” Immunity 51, no. 2 (2019): 337-350.e7.

[2] J. Stavnezer, J. E. Guikema, and C. E. Schrader, “Mechanism and Regulation of Class Switch Recombination,” Annual Review of Immunology 26 (2008): 261-292.

[3] A. J. Matthews, S. Zheng, L. J. DiMenna, and J. Chaudhuri, “Regulation of Immunoglobulin Class-Switch Recombination: Choreography of Noncoding Transcription, Targeted DNA Deamination, and Long-Range DNA Repair,” Advances in Immunology 122 (2014): 1-57.

[4] J. E. Guikema, E. K. Linehan, D. Tsuchimoto, et al., “APE1- and APE2-Dependent DNA Breaks in Immunoglobulin Class Switch Recombination,” Journal of Experimental Medicine 204, no. 12 (2007): 3017-3026.

[5] M. Muramatsu, K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo, “Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme,” Cell 102, no. 5 (2000): 553-563.

[6] C. Rada, G. T. Williams, H. Nilsen, D. E. Barnes, T. Lindahl, and M. S. Neuberger, “Immunoglobulin Isotype Switching is Inhibited and Somatic Hypermutation Perturbed in UNG-Deficient Mice,” Current Biology 12, no. 20 (2002): 1748-1755.

[7] A. Rolink and F. Melchers, “Molecular and Cellular Origins of B Lymphocyte Diversity,” Cell 66, no. 6 (1991): 1081-1094.

[8] R. Maddaly, G. Pai, S. Balaji, et al., “Receptors and Signaling Mechanisms for B-Lymphocyte Activation, Proliferation and Differentiation-Insights From Both In Vivo and In Vitro Approaches,” FEBS Letters 584, no. 24 (2010): 4883-4894.

[9] T. Kawabe, T. Naka, K. Yoshida, et al., “The Immune Responses in CD40-Deficient Mice: Impaired Immunoglobulin Class Switching and Germinal Center Formation,” Immunity 1, no. 3 (1994): 167-178.

[10] C. M. Snapper and J. J. Mond, “Towards a Comprehensive View of Immunoglobulin Class Switching,” Immunology Today 14, no. 1 (1993): 15-17.

[11] G. A. Daniels and M. R. Lieber, “RNA:DNA Complex Formation Upon Transcription of Immunoglobulin Switch Regions: Implications for the Mechanism and Regulation of Class Switch Recombination,” Nucleic Acids Research 23, no. 24 (1995): 5006-5011.

[12] M. E. Reaban and J. A. Griffin, “Induction of RNA-Stabilized DNA Conformers by Transcription of an Immunoglobulin Switch Region,” Nature 348, no. 6299 (1990): 342-344.

[13] M. Lorenz, S. Jung, and A. Radbruch, “Switch Transcripts in Immunoglobulin Class Switching,” Science 267, no. 5205 (1995): 1825-1828.

[14] M. CognÉ and B. K. Birshtein, “Regulation of class switch recombination,” in Molecular Biology of B Cells, ed. T. Honjo, F. W. Alt, M. S. Neuberger (Academic Press, 2004), 289-305.

[15] J. Stavnezer, “Immunoglobulin Class Switching,” Current Opinion in Immunology 8, no. 2 (1996): 199-205.

[16] C. Ribeiro de Almeida, S. Dhir, A. Dhir, et al., “RNA Helicase DDX1 Converts RNA G-Quadruplex Structures Into R-Loops to Promote IgH Class Switch Recombination,” Molecular Cell 70, no. 4 (2018): 650-662.e8.

[17] J. Chen, Z. Cai, M. Bai, et al., “The RNA-Binding Protein ROD1/PTBP3 Cotranscriptionally Defines AID-loading Sites to Mediate Antibody Class Switch in Mammalian Genomes,” Cell Research 28, no. 10 (2018): 981-995.

[18] N. A. Begum, F. Haque, A. Stanlie, et al., “Phf5a Regulates DNA Repair in Class Switch Recombination via p400 and Histone H2A Variant Deposition,” EMBO Journal 40, no. 12 (2021): e106393.

[19] J. Chaudhuri, M. Tian, C. Khuong, K. Chua, E. Pinaud, and F. W. Alt, “Transcription-Targeted DNA Deamination by the AID Antibody Diversification Enzyme,” Nature 422, no. 6933 (2003): 726-730.

[20] M. D. Diaz-Muñoz, S. E. Bell, and K. Fairfax, et al., “The RNA-Binding Protein HuR is Essential for the B Cell Antibody Response,” Nature Immunology 16, no. 4 (2015): 415-425.

[21] H. Huang, Y. Li, G. Zhang, et al., “The RNA-Binding Protein hnRNP F is Required for the Germinal Center B Cell Response,” Nature Communications 14, no. 1 (2023): 1731.

[22] E. Monzón-Casanova, M. Screen, M. D. Díaz-Muñoz, et al., “The RNA-Binding Protein PTBP1 is Necessary for B Cell Selection in Germinal Centers,” Nature Immunology 19, no. 3 (2018): 267-278.

[23] N. M. Martinez and K. W. Lynch, “Control of Alternative Splicing in Immune Responses: Many Regulators, Many Predictions, Much Still to Learn,” Immunological Reviews 253, no. 1 (2013): 216-236.

[24] L. Sun, J. Chen, R. Ye, et al., “SRSF1 is Crucial for Male Meiosis Through Alternative Splicing During Homologous Pairing and Synapsis in Mice,” Science Bulletin 68, no. 11 (2023): 1100-1104.

[25] M. Ning, Q. Li, Y. Wang, et al., “Alternative Splicing Drives the Functional Diversification of a bHLH Transcription Factor in the Control of Growth and Drought Tolerance in Rice,” Science Bulletin (Beijing) 70, 153-156. (2024).

[26] C. Yang, A. Luo, H. P. Lu, S. J. Davis, and J. X. Liu, “Diurnal Regulation of Alternative Splicing Associated With Thermotolerance in Rice by Two Glycine-Rich RNA-Binding Proteins,” Science Bulletin (Beijing) 69, no. 1 (2024): 59-71.

[27] H. H. Wei, X. J. Fan, Y. Hu, et al., “A Systematic Survey of PRMT Interactomes Reveals the Key Roles of Arginine Methylation in the Global Control of RNA Splicing and Translation,” Science Bulletin (Beijing) 66, no. 13 (2021): 1342-1357.

[28] P. Ajuh, “Functional Analysis of the human CDC5L Complex and Identification of Its Components by Mass Spectrometry,” EMBO Journal 19, no. 23 (2000): 6569-6581.

[29] K. Nagasaki, N. Maass, T. Manabe, et al., “Identification of a Novel Gene, DAM1, Amplified at Chromosome 1p13.3-21 Region in Human Breast Cancer Cell Lines,” Cancer Letters 140, no. 1-2 (1999): 219-226.

[30] S. P. Chan, D. I. Kao, W. Y. Tsai, and S. C. Cheng, “The Prp19p-Associated Complex in Spliceosome Activation,” Science (New York, NY) 302, no. 5643 (2003): 279-282.

[31] S. Bessonov, M. Anokhina, C. L. Will, H. Urlaub, and R. Lührmann, “Isolation of an Active Step I Spliceosome and Composition of Its RNP Core,” Nature 452, no. 7189 (2008): 846-850.

[32] W. Liu, F. Wang, Q. Xu, et al., “BCAS2 is Involved in Alternative mRNA Splicing in Spermatogonia and the Transition to Meiosis,” Nature Communications 8 (2017): 14182.

[33] X. Yao, C. Wang, W. Yu, et al., “BCAS2 Regulates Oocyte Meiotic Prophase I by Participating in mRNA Alternative Splicing,” FASEB Journal 38, no. 1 (2024): e23361.

[34] J. Zhang, W. Liu, G. Li, et al., “BCAS2 is Involved in Alternative Splicing and Mouse Oocyte Development,” FASEB Journal 36, no. 2 (2022): e22128.

[35] X. Chen, X. Xie, J. Li, et al., “BCAS2 Participates in Insulin Synthesis and Secretion via mRNA Alternative Splicing in Mice,” Endocrinology 165, no. 1 (2023): bqad152.

[36] P. C. Kuo, C. W. Huang, C. I. Lee, et al., “BCAS2 Promotes Prostate Cancer Cells Proliferation by Enhancing AR mRNA Transcription and Protein Stability,” British Journal of Cancer 112, no. 2 (2015): 391-402.

[37] B. Lang and S. Zhao, “miR-486 Functions as a Tumor Suppressor in Esophageal Cancer by Targeting CDK4/BCAS2,” Oncology Reports 39, no. 1 (2018): 71-80.

[38] S. Yu, T. Jiang, D. Jia, et al., “BCAS2 is Essential for Hematopoietic Stem and Progenitor Cell Maintenance During Zebrafish Embryogenesis,” Blood 133, no. 8 (2019): 805-815.

[39] Q. Xu, F. Wang, Y. Xiang, et al., “Maternal BCAS2 Protects Genomic Integrity in Mouse Early Embryonic Development,” Development 142, no. 22 (2015): 3943-3953.

[40] M. Nakamura, S. Kondo, M. Sugai, M. Nazarea, S. Imamura, and T. Honjo, “High Frequency Class Switching of an IgM+ B Lymphoma Clone CH12F3 to IgA+ Cells,” International Immunology 8, no. 2 (1996): 193-201.

[41] P. D. Hodgkin, J. H. Lee, and A. B. Lyons, “B Cell Differentiation and Isotype Switching is Related to Division Cycle Number,” Journal of Experimental Medicine 184, no. 1 (1996): 277-281.

[42] J. T. Robinson, H. Thorvaldsdóttir, W. Winckler, et al., “Integrative Genomics Viewer,” Nature Biotechnology 29, no. 1 (2011): 24-26.

[43] X. Zhou, W. Wu, H. Li, et al., “Transcriptome Analysis of Alternative Splicing Events Regulated by SRSF10 Reveals Position-Dependent Splicing Modulation,” Nucleic Acids Research 42, no. 6 (2014): 4019-4030.

[44] L. Cvetkovic, S. Perisic, J. Titze, H. M. Jäck, and W. Schuh, “The Impact of Hyperosmolality on Activation and Differentiation of B Lymphoid Cells,” Frontiers in Immunology 10 (2019): 828.

[45] C. Pan, N. Baumgarth, and J. R. Parnes, “CD72-Deficient Mice Reveal Nonredundant Roles of CD72 in B Cell Development and Activation,” Immunity 11, no. 4 (1999): 495-506.

[46] C. Akatsu, T. Tsuneshige, N. Numoto, et al., “CD72 is an Inhibitory Pattern Recognition Receptor That Recognizes Ribosomes and Suppresses Production of Anti-Ribosome Autoantibody,” Journal of Autoimmunity 146 (2024): 103245.

[47] L. D. Notarangelo and A. R. Hayward, “X-Linked Immunodeficiency With Hyper-IgM (XHIM),” Clinical and Experimental Immunology 120, no. 3 (2000): 399-405.

[48] A. Bhushan and L. R. Covey, “CD40:CD40L Interactions in X-Linked and Non-X-Linked Hyper-IgM Syndromes,” Immunologic Research 24, no. 3 (2001): 311-324.

[49] L. Nair, W. Zhang, B. Laffleur, et al., “Mechanism of Noncoding RNA-Associated N6-Methyladenosine Recognition by an RNA Processing Complex During IgH DNA Recombination,” Molecular Cell 81, no. 19 (2021): 3949-3964.e7.

[50] J. Sun, C. D. Keim, J. Wang, et al., “E3-Ubiquitin Ligase Nedd4 Determines the Fate of AID-Associated RNA Polymerase II in B Cells,” Genes & Development 27, no. 16 (2013): 1821-1833.

[51] F. L. Li, A. F. Liu, and Y. J. Chen, “Research Progress on the Role of Musashi-2 in the Pathogenesis of Malignant Hematologic Diseases-Review,” Zhongguo Shi Yan Xue Ye Xue Za Zhi 25, no. 2 (2017): 633-636.

[52] Y. Yang, M. Zhao, T. Ding, C. Ni, Q. Zheng, and X. Li, “Advances in Research of Musashi2 in Solid Tumors,” Journal of Southern Medical University 42, no. 3 (2022): 448-456.

[53] J. R. Parnes and C. Pan, “CD72, a Negative Regulator of B-Cell Responsiveness,” Immunological Reviews 176 (2000): 75-85.

[54] H. M. Scott, M. H. Smith, A. K. Coleman, et al., “Serine/Arginine-Rich Splicing Factor 7 Promotes the Type I Interferon Response by Activating Irf7 Transcription,” Cell Reports 43, no. 3 (2024): 113816.

[55] D. Li, J. Guo, and R. Jia, “Epigenetic Control of Cancer Cell Proliferation and Cell Cycle Progression by HNRNPK via Promoting Exon 4 Inclusion of Histone Code Reader SPIN1,” Journal of Molecular Biology 435, no. 6 (2023): 167993.

[56] N. O. Gekara, “DNA Damage-Induced Immune Response: Micronuclei Provide Key Platform,” Journal of Cell Biology 216, no. 10 (2017): 2999-3001.

[57] X. D. Fu, M. Ares Jr., “Context-Dependent Control of Alternative Splicing by RNA-Binding Proteins,” Nature Reviews Genetics 15, no. 10 (2014): 689-701.

[58] J. Giudice and H. Jiang, “Splicing Regulation Through Biomolecular Condensates and Membraneless Organelles,” Nature Reviews Molecular Cell Biology 25 (2024): 683-700.

[59] J. Chen and Y. Xue, “Emerging Roles of Non-Coding RNAs in Epigenetic Regulation,” Science China Life Sciences 59, no. 3 (2016): 227-235.

[60] R. Pavri, A. Gazumyan, and M. Jankovic, et al., “Activation-Induced Cytidine Deaminase Targets DNA at Sites of RNA Polymerase II Stalling by Interaction With Spt5,” Cell 143, no. 1 (2010): 122-133.

[61] Z. Xu, Z. Fulop, G. Wu, et al., “14-3-3 Adaptor Proteins Recruit AID to 5'-AGCT-3'-Rich Switch Regions for Class Switch Recombination,” Nature Structural & Molecular Biology 17, no. 9 (2010): 1124-1135.

[62] J. Chaudhuri, C. Khuong, and F. W. Alt, “Replication Protein A Interacts With AID to Promote Deamination of Somatic Hypermutation Targets,” Nature 430, no. 7003 (2004): 992-998.

[63] M. S. Wold, “Replication Protein A: A Heterotrimeric, Single-Stranded DNA-Binding Protein Required for Eukaryotic DNA Metabolism,” Annual Review of Biochemistry 66 (1997): 61-92.

[64] C. J. Wright, C. W. J. Smith, and C. D. Jiggins, “Alternative Splicing as a Source of Phenotypic Diversity,” Nature Reviews Genetics 23, no. 11 (2022): 697-710.

[65] K. Kwon, C. Hutter, Q. Sun, et al., “Instructive Role of the Transcription Factor E2A in Early B Lymphopoiesis and Germinal Center B Cell Development,” Immunity 28, no. 6 (2008): 751-762.

[66] P. Casali, T. Shen, Y. Xu, et al., “Estrogen Reverses HDAC Inhibitor-Mediated Repression of Aicda and Class-Switching in Antibody and Autoantibody Responses by Downregulation of miR-26a,” Frontiers in Immunology 11 (2020): 491.

[67] K. G. Smith, “The Extent of Affinity Maturation Differs Between the Memory and Antibody-Forming Cell Compartments in the Primary Immune Response,” EMBO Journal 16, no. 11 (1997): 2996-3006.

[68] M. Hagn, G. T. Belz, A. Kallies, et al., “Activated Mouse B Cells Lack Expression of Granzyme B,” Journal of Immunology (Baltimore, Md: 1950) 188, no. 8 (2012): 3886-3892.

[69] E. Fuc, D. Złotkowska, E. Wasilewska, and B. Wróblewska, “OVA-Experienced CD4(+) T Cell Transfer and Chicken Protein Challenge Affect the Immune Response to OVA in a Murine Model,” International Journal of Molecular Sciences 22, no. 12 (2021): 6573.

[70] B. J. Quah, H. S. Warren, and C. R. Parish, “Monitoring Lymphocyte Proliferation In Vitro and In Vivo With the Intracellular Fluorescent Dye Carboxyfluorescein Diacetate Succinimidyl Ester,” Nature Protocols 2, no. 9 (2007): 2049-2056.

[71] C. He, S. Wang, C. Zhou, et al., “CD36 and LC3B Initiated Autophagy in B Cells Regulates the Humoral Immune Response,” Autophagy 17, no. 11 (2021): 3577-3591.

[72] M. I. Love, W. Huber, and S. Anders, “Moderated Estimation of Fold Change and Dispersion for RNA-seq Data With DESeq2,” Genome Biology 15, no. 12 (2014): 550.

[73] E. L. Van Nostrand, G. A. Pratt, A. A. Shishkin, et al., “Robust Transcriptome-Wide Discovery of RNA-Binding Protein Binding Sites With Enhanced CLIP (eCLIP),” Nature Methods 13, no. 6 (2016): 508-514.

[74] L. Sun, Z. Lv, X. Chen, et al., “Splicing Factor SRSF1 is Essential for Homing of Precursor Spermatogonial Stem Cells in Mice,” Elife 12 (2024): RP89316.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.